A Study To Evaluate The Safety And Pharmacokinetic Profile Of A P38 Inhibitor (PH-797804) In Subjects With Rheumatoid Arthritis Who Are Also Taking Methotrexate
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Pfizer
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Adult with RA for at least 6 months
Stable weekly dosage of oral methotrexate 12.5- 25 mg/week
You may not be if
Severe, progressive and/or uncontrolled other disease
Chronic or recent serious infection; current infection
Concomitant use of RA therapy other than methotrexate with some exceptions
Clareo Health | A Study To Evaluate The Safety And Pharmacokinetic Profile Of A P38 Inhibitor (PH-797804) In Subjects With Rheumatoid Arthritis Who Are Also Taking Methotrexate
